The evidence from published intervention trials is consistent: T/T individuals receiving adequate 5-MTHF + B12 + B6 supplementation normalize plasma homocysteine to levels similar to C/C individuals, restore BH4 availability and endothelial function, and reduce the functional consequences of MTHFR impairment across most of the five longevity mechanisms described above
Patients with diabetes using insulin or sulfonylureas with GLP-1 agents have an increased risk of hypoglycemia and may need dose adjustments of these medications
By week 12, your body and the medication have established a stable rhythm, and your appetite suppression reaches its plateau at your current dose
doi: 10.1183/13993003.00970-2022 123 SotznyFFilgueirasISKedorCFreitagHWittkeKBauerSet al
In SURMOUNT-4, participants who completed a 36-week open-label lead-in had a mean weight reduction of 20.9% by week 36
Mounjaro is already FDA-approved to treat type 2 diabetes, and some Medicare Part D plans may cover the costs of both drugs when a doctor prescribes them for reasons other than weight loss